VivoSeq
Psychiatry

Social Anxiety Disorder (SAD)

3

Pipeline Programs↗

3

Active Trials↗

4

Companies Involved↗

Social Anxiety Disorder (SAD) is an early-stage landscape with 3 programs across 4 companies. The most active players are Ono Pharmaceutical Co. Ltd, Newleos Therapeutics, Inc., Vanda Pharmaceuticals. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd

1 program

Phase 2N

Newleos Therapeutics, Inc.

1 program

Phase 2V

Vanda Pharmaceuticals

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 22

ONO-1110

Ono Pharmaceutical Co. Ltd

NTX-1472

Newleos Therapeutics, Inc.

Phase 31

VQW-765

Vanda Pharmaceuticals

Approved
No programs

Analysis

Trial Status

4

clinical trials

Recruiting3 · 75%
Completed1 · 25%

Clinical Trials

Trial Activity

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of NTX-1472, a V1a Receptor Antagonist, in Adults With Social Anxiety Disorder
Recruiting·NNewleos Therapeutics, Inc.·Phase 2·NCT07323784·100 enrolled
A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Social Anxiety Disorder
Completed·Ono Pharmaceutical Co. Ltd logoOno Pharmaceutical Co. Ltd·Phase 2·NCT06805565·115 enrolled
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Acute Anxiety in Patients With Social Anxiety Disorder
Recruiting·VVanda Pharmaceuticals·Phase 3·NCT07221578·500 enrolled
Placebo Effects in Dot-Probe Attention Bias Modification (ABM) Among Adults With Social Anxiety Disorder.
Recruiting·TTel Aviv University·Preclinical·NCT07666776·90 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)